Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thioridazine + Cytarabine in Relapsed/Refractory AML
NCT02096289Phase 1Completed
- Sponsor
- Ontario Clinical Oncology Group
- Start
- Jul 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thioridazine in acute myeloid leukemia (AML), sponsored by Ontario Clinical Oncology Group. Primary endpoint: Safety up to 36 days. Started Jul 2014; status: completed.
02
Drugs
thioridazine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02096289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096289.